Efficacy of methylprednisolone pulse therapy in patients with COVID-19
Objective. To assess efficacy and safety of methylprednisolone pulse therapy in patients with COVID-19. Materials and Methods. A retrospective analysis of 57 patients with moderate and severe novel coronavirus infection (COVID-19) receiving methylprednisolone pulse therapy (500 mg/day IV for 2–3 consecutive days) was performed. Pre- and post-therapy examination of the patients included clinical (severity and duration of fever, gas exchange parameters), imaging (computed tomography) and laboratory tests (including C-reactive protein, procalcitonin, D-dimer). Results. Methylprednisolone pulse therapy resulted in improved gas exchange (the mean duration of SpO2 recovery was 3.9 ± 0.25 days), body temperature normalization (the mean time to defervescence was 2.1 ± 0.2 days), significant decrease in inflammatory marker levels (CRP, D-dimer). No patients required an enhancement of respiratory support (transfer to ICU). Methylprednisolone pulse therapy was well-tolerated and did not cause bacterial complications. Conclusions. Methylprednisolone pulse therapy in patients with COVID-19 was shown to decrease activity of systemic inflammatory response, severity of coagulation disorders and contribute to recovery of gas exchange lung function. Given the high efficacy and low cost of methylprednisolone pulse therapy, it could be one of the promising approaches to the management of patients with moderate and severe COVID-19. Further studies are needed to determine prognostic criteria of progression and optimal time for initiation of corticosteroid therapy..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Клиническая микробиология и антимикробная химиотерапия - 22(2020), 2, Seite 88-91 |
Sprache: |
Russisch |
---|
Beteiligte Personen: |
zaicev_aa [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Corticosteroids |
---|
doi: |
10.36488/cmac.2020.2.88-91 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ043961193 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ043961193 | ||
003 | DE-627 | ||
005 | 20230308075116.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2020 xx |||||o 00| ||rus c | ||
024 | 7 | |a 10.36488/cmac.2020.2.88-91 |2 doi | |
035 | |a (DE-627)DOAJ043961193 | ||
035 | |a (DE-599)DOAJ1fc6c47e7be242d8a19fcaa8e44a24bf | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a rus | ||
050 | 0 | |a RC109-216 | |
050 | 0 | |a QR1-502 | |
100 | 0 | |a zaicev_aa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy of methylprednisolone pulse therapy in patients with COVID-19 |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Objective. To assess efficacy and safety of methylprednisolone pulse therapy in patients with COVID-19. Materials and Methods. A retrospective analysis of 57 patients with moderate and severe novel coronavirus infection (COVID-19) receiving methylprednisolone pulse therapy (500 mg/day IV for 2–3 consecutive days) was performed. Pre- and post-therapy examination of the patients included clinical (severity and duration of fever, gas exchange parameters), imaging (computed tomography) and laboratory tests (including C-reactive protein, procalcitonin, D-dimer). Results. Methylprednisolone pulse therapy resulted in improved gas exchange (the mean duration of SpO2 recovery was 3.9 ± 0.25 days), body temperature normalization (the mean time to defervescence was 2.1 ± 0.2 days), significant decrease in inflammatory marker levels (CRP, D-dimer). No patients required an enhancement of respiratory support (transfer to ICU). Methylprednisolone pulse therapy was well-tolerated and did not cause bacterial complications. Conclusions. Methylprednisolone pulse therapy in patients with COVID-19 was shown to decrease activity of systemic inflammatory response, severity of coagulation disorders and contribute to recovery of gas exchange lung function. Given the high efficacy and low cost of methylprednisolone pulse therapy, it could be one of the promising approaches to the management of patients with moderate and severe COVID-19. Further studies are needed to determine prognostic criteria of progression and optimal time for initiation of corticosteroid therapy. | ||
650 | 4 | |a novel coronavirus infection | |
650 | 4 | |a covid-19 | |
650 | 4 | |a corticosteroids | |
650 | 4 | |a methylprednisolone | |
650 | 4 | |a pulse therapy | |
653 | 0 | |a Infectious and parasitic diseases | |
653 | 0 | |a Microbiology | |
700 | 0 | |a Golukhova E.Z. |e verfasserin |4 aut | |
700 | 0 | |a Mamalyga M.L. |e verfasserin |4 aut | |
700 | 0 | |a Chernov S.A. |e verfasserin |4 aut | |
700 | 0 | |a Rybka M.M. |e verfasserin |4 aut | |
700 | 0 | |a Kryukov E.V. |e verfasserin |4 aut | |
700 | 0 | |a Klyuchnikov I.V. |e verfasserin |4 aut | |
700 | 0 | |a Semyonov V.Yu. |e verfasserin |4 aut | |
700 | 0 | |a Orlov I.N. |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Клиническая микробиология и антимикробная химиотерапия |d Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy, 2019 |g 22(2020), 2, Seite 88-91 |w (DE-627)DOAJ000042331 |x 26869586 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2020 |g number:2 |g pages:88-91 |
856 | 4 | 0 | |u https://doi.org/10.36488/cmac.2020.2.88-91 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/1fc6c47e7be242d8a19fcaa8e44a24bf |z kostenfrei |
856 | 4 | 0 | |u https://cmac-journal.ru/publication/2020/2/cmac-2020-t22-n2-p088/cmac-2020-t22-n2-p088.pdf |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1684-4386 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2686-9586 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 22 |j 2020 |e 2 |h 88-91 |